Compared with other markets, the US has a high percentage of ovarian and primary peritoneal cancers that are diagnosed at stage IV.

While less than 15% of ovarian and primary peritoneal cancers are diagnosed at stage IV in France, Germany, Italy, and Spain, more than 30% are diagnosed at this stage in the US. This disparity is displayed in Figure 1.

For a cancer with a low survival rate, such as ovarian cancer, earlier diagnosis could be a critical step in improving outcomes. Ovarian cancer, cancer of the fallopian tubes, and other uterine adnexa are leading causes of cancer-related mortality in women.

The American Cancer Society estimates that in 2017, 22,440 women will be diagnosed and 14,080 women will die from ovarian cancer in the US. Worldwide, this disease is the seventh most common cancer in women and it is estimated that more than 230,000 cases were diagnosed in 2012 around the world. The five-year survival rate ranges from 30%–50% globally. The low survival rate is mainly the result of its late detection once the disease has progressed to a more advanced stage.

Despite the high percentage of ovarian cancer cases that are diagnosed at stage IV, the US has a higher five-year survival rate than other markets. While this may be partly driven by high quality of care, it could also be affected by the specific type of ovarian cancers that occur in the US. Improved screening and diagnosis could help the US improve its survival rates even more.

Details about the trend analysis and other discussions of ovarian cancer epidemiology can be found in the EpiCast Report: 'Ovarian and Primary Peritoneal Cancer – Epidemiology Forecast to 2025' and the EpiCast Model: 'Ovarian and Primary Peritoneal Cancer – Epidemiology Forecast to 2025.'